CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 24, 2023--Ankyra Therapeutics, a clinical stage biotechnology company pioneering anchored immunotherapies to treat cancer, today announced approval of its investigational new drug (IND) application by the U.S. Food & Drug Administration (FDA) ...
SAN FRANCISCO & LONDON--(BUSINESS WIRE)--Oct 24, 2023--Aiolos Bio, Inc. (鈥淎iolos鈥� or 鈥渢he Company鈥�) today announced its launch as a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with respiratory and inflammatory ...
NANTES, France--(BUSINESS WIRE)--Oct 23, 2023--Regulatory News:<em>OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)</em> today announced that first Phase 1 results for BI 770371, a novel anti-SIRPa monoclonal antibody evaluated in advanced solid tumors, ...
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Oct 23, 2023--Positive results from the ongoing <a ...
WILMINGTON, Del.--(BUSINESS WIRE)--Oct 23, 2023--Positive results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed that ENHERTU庐 (fam-trastuzumab deruxtecan-nxki) continued to demonstrate clinically meaningful and durable responses, leading to a clinically ...
<p style="TEXT-ALIGN:CENTER">Data from the QUASAR induction study of adults with moderate to severely active ulcerative colitis show clinically meaningful results at Weeks 12 or 24<p style="TEXT-ALIGN:CENTER">Additional data show symptomatic response as early as one ...